P·01 Pipeline — clones in development
Among cancer-immunology checkpoint markers, we put a strong focus on the highly complex TIGIT axis. With TG1 and TG2 (TIGIT) and R12 (CD112R/PVRIG), key receptors of this axis are already covered by released clones. The next target in development is CD155 — the ligand at the centre of this axis.
P·02 In development
CD155 (poliovirus receptor, PVR) is the shared ligand of two opposing receptor systems on natural killer cells and T cells: it binds the costimulatory receptor CD226 as well as the co-inhibitory receptors TIGIT and CD96. Whether an immune cell is activated or held back therefore depends on which of these receptors engages CD155 in the tissue.
This complexity is best examined with several antibody clones that bind different epitopes of CD155. We are therefore developing additional CD155 clones as a complement to our released clones against TIGIT (TG1, TG2) and CD112R/PVRIG (R12), so that the TIGIT axis can be studied on both the receptor and the ligand side in the same tissue.
P·03 Where we stand
The CD155 candidate clones are at an early stage: they are not yet verified. At present they exist as hybridoma culture supernatants. The next step is immunohistochemical testing of these supernatants on formalin-fixed, paraffin-embedded (FFPE) tissue to establish whether each clone stains CD155 specifically — the same path our released clones have taken through ULTRA validation.
Pathologists and research laboratories who would like to take part in this evaluation phase — testing the CD155 candidate clones by IHC on their own FFPE material — are welcome to contact us by e-mail: info@oncodianova.com.
For Research Use Only. Not for diagnostic or therapeutic use.